What is Ultragenyx Pharmaceutical Inc. Quarterly Revenue?

Ultragenyx Pharmaceutical Inc. Quarterly Revenue Ultragenyx Pharmaceutical Inc Jun-2026 Quarterly Revenue is $214 Million which is growth of 28.5% YoY.

What is Ultragenyx Pharmaceutical Inc. Quarterly Net Profit?

Ultragenyx Pharmaceutical Inc. Quarterly Net Profit Ultragenyx Pharmaceutical Inc Jun-2026 Quarterly Net Profit is $-92 Million which is growth of 20.0% YoY.

What is Ultragenyx Pharmaceutical Inc. Annual Revenue?

Ultragenyx Pharmaceutical Inc. Annual Revenue Ultragenyx Pharmaceutical Inc Dec-2025 Annual Revenue is $673 Million which is growth of 20.1% YoY.

What is Ultragenyx Pharmaceutical Inc. Annual Net Profit?

Ultragenyx Pharmaceutical Inc. Annual Net Profit Ultragenyx Pharmaceutical Inc Dec-2025 Annual Net Profit is $-575 Million which is growth of -1.0% YoY.

What is Ultragenyx Pharmaceutical Inc. Total Shareholders Fund?

Ultragenyx Pharmaceutical Inc. Total Shareholders Fund Ultragenyx Pharmaceutical Inc Dec-2025 Total Shareholders Fund is $-80 Million which is growth of -131.3% YoY.

What is Ultragenyx Pharmaceutical Inc. Total Assets?

Ultragenyx Pharmaceutical Inc. Total Assets Ultragenyx Pharmaceutical Inc Dec-2025 Total Assets is $1,532 Million which is growth of 1.9% YoY.

What is Ultragenyx Pharmaceutical Inc. Book Value Per Share?

Ultragenyx Pharmaceutical Inc. Book Value Per Share Ultragenyx Pharmaceutical Inc Book Value Per Share is $-3 which is growth of -288.0% YoY.

What is Ultragenyx Pharmaceutical Inc. ROE?

Ultragenyx Pharmaceutical Inc. ROE Ultragenyx Pharmaceutical Inc ROE is 0% which is growth of 0% YoY.

What is Ultragenyx Pharmaceutical Inc. Cash From Operating Activity?

Ultragenyx Pharmaceutical Inc. Cash From Operating Activity Ultragenyx Pharmaceutical Inc Dec-2025 Cash From Operating Activity is $-466 Million which is growth of -12.5% YoY.

What is Ultragenyx Pharmaceutical Inc. Net Cash Flow?

Ultragenyx Pharmaceutical Inc. Net Cash Flow Ultragenyx Pharmaceutical Inc Dec-2025 Net Cash Flow is $248 Million which is growth of 858.1% YoY.

Ultragenyx Pharmaceutical Inc.

XNAS: RARE

Download real time

-0.72(-4.73%)

63.65% Fall from 52W High

4.7M

XNAS Volume

XNAS 05 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Ultragenyx Pharmaceutical Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Ultragenyx Pharmaceutical Inc share price target, revenues, EPS, net income and more

Ultragenyx Pharmaceutical Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

Nested row level

Base Level

Export

POSITIVE
Quarterly Revenue Ultragenyx Pharmaceutical Inc Jun-2026 Quarterly Revenue is $214 Million which is growth of 28.5% YoY.
POSITIVE
Quarterly Net Profit Ultragenyx Pharmaceutical Inc Jun-2026 Quarterly Net Profit is $-92 Million which is growth of 20.0% YoY.

Ultragenyx Pharmaceutical Inc., Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
Indicator	Jun '26	Mar '26	Dec '25	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24	Mar '24	Dec '23	Sep '23	Jun '23
SR_Q Operating Rev.	214	136	207.3	159.9	166.5	139.3	164.9	139.5	147	108.8	127.4	98.1	108.3
CostOfRevenue_Q Cost Of Rev.	34	30	29.3	28	23	28.7	16.9	21	21.3	17.5	12.1	11	9.9
GrossProfit_Q Gross Profit	180	106	177.9	131.9	143.5	110.6	148	118.5	125.8	91.3	115.3	87.1	98.4
OEXPNS_Q Operating Exp. ⌄	255	275	291.2	302.8	251.4	253.6	270.3	250.5	242.1	256.7	237.4	232.2	246.4
AdminAndSellingExpenses_Q Admin Plus Selling Exp.	88	88	87.9	86.6	86.7	87.8	82.5	80.4	80.6	78.2	76.8	74.9	81.4
ResearchAndDevlopmentExpenses_Q RnD Exp.	167	187	203.3	216.2	164.7	165.8	187.8	170.1	161.5	178.5	160.6	157.2	165
OP_Q Operating Profit	-75	-169	-113.3	-170.9	-107.9	-142.9	-122.3	-132	-116.4	-165.4	-122.1	-145.1	-148
NetNonOperIntIncExp_Q Net Non Operations Interest Incuding Expenses ⌄	-17	-15	-13	-8.3	-8.3	-7.5	-6	-5	-8.6	-7	-8.8	-11.8	-9.4
Others_Q Other Interest Earned	5	6	6.5	5.9	5.8	6.8	9.6	10.7	7.4	8.8	8.6	5.9	6
IntExpNonOperating_Q Interest Exp. Non Operating	22	21	19.5	14.2	14	14.3	15.5	15.7	16	15.9	17.3	17.7	15.4
PBT_Q Profit Before Tax	-91	-184	-127.7	-179.5	-114	-149.8	-133.4	-133.2	-130.7	-170.2	-126.9	-159	-159.1
TAX_Q Tax	1	1	0.9	0.9	1	1.3	-0	0.3	0.9	0.5	-3.7	0.7	0.7
NICommonStockholders_Q Net Income Common Stockholders ⌄	-92	-185	-128.6	-180.4	-115	-151.1	-133.4	-133.5	-131.6	-170.7	-123.2	-159.7	-159.8
NP_Q Net Profit	-92	-185	-128.6	-180.4	-115	-151.1	-133.4	-133.5	-131.6	-170.7	-123.2	-159.7	-159.8
NIIncludingNoncontrollingInterests_Q Net Income Including Non controlling Interests	-92	-185	-128.6	-180.4	-115	-151.1	-133.4	-133.5	-131.6	-170.7	-123.2	-159.7	-159.8
DilutedNIAvailtoComStockholders_Q Diluted NI Avail to Com Stockholders Ann.	-92	-185	-128.6	-180.4	-115	-151.1	-133.4	-133.5	-131.6	-170.7	-123.2	-159.7	-159.8
EPS_Q Basic EPS	-0.9	-1.8	-1.3	-1.8	-1.2	-1.6	-1.4	-1.4	-1.5	-2	-1.5	-2.2	-2.3
AfterDilutedEPS_Q Diluted EPS After ExtraOrdinary	-0.9	-1.8	-1.3	-1.8	-1.2	-1.6	-1.4	-1.4	-1.5	-2.1	-1.5	-2.2	-2.3
SHARE_Q Number Of Shares End	101.9	100.6	99.8	99.8	98.5	96.3	95.7	95.5	86.6	84.3	81.2	71.7	70.9
NIContinuingDiscontinuedOper_Q Net Income Continuing Discontinued Operations	-92	-185	-128.6	-180.4	-115	-151.1	-133.4	-133.5	-131.6	-170.7	-123.2	-159.7	-159.8
NormalizedIncome_Q Normalized Income	-92	-185	-128.6	-181	-114.9	-151	-131.8	-134.1	-128.5	-173.6	-125	-158.5	-160
InterestIncome_Q Interest Income	5	6	6.5	5.9	5.8	6.8	9.6	10.7	7.4	8.8	8.6	5.9	6
INT_Q Interest	22	21	19.5	14.2	14	14.3	15.5	15.7	16	15.9	17.3	17.7	15.4
NetInterestIncome_Q Net Interest Income	-17	-15	-13	-8.3	-8.3	-7.5	-6	-5	-8.6	-7	-8.8	-11.8	-9.4
EBIT_Q EBIT	-69	-163	-108.2	-165.4	-100	-135.4	-117.9	-117.5	-114.8	-154.4	-109.6	-141.3	-143.7
EBITDA_Q EBITDA	-61	-155	-99.4	-156.8	-91.3	-126.4	-108.8	-108.7	-105.9	-145.5	-101.4	-134.1	-138.4
ReconciledCostOfRevenue_Q Reconciled Cost Of Rev.	34	30	29.3	28	23	28.7	16.9	21	21.3	17.5	12.1	11	9.9
ReconciledDepreciation_Q Reconciled Depr.	8	8	8.8	8.6	8.6	9	9.1	8.8	8.9	8.9	8.2	7.2	5.4
ProfitLossFromContinuingOperations_Q Profit From Continuing Operations	-92	-185	-128.6	-180.4	-115	-151.1	-133.4	-133.5	-131.6	-170.7	-123.2	-159.7	-159.8
NormalizedEBITDA_Q Normalized EBITDA	-61	-155	-99.4	-157.5	-91.3	-126.3	-107.3	-109.4	-101.9	-149.3	-103.2	-132.7	-138.6

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Ultragenyx Pharmaceutical Inc competitor comparison and performance snapshot within industry

Ultragenyx Pharmaceutical Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Annual Revenue Ultragenyx Pharmaceutical Inc Dec-2025 Annual Revenue is $673 Million which is growth of 20.1% YoY.
NEGATIVE
Annual Net Profit Ultragenyx Pharmaceutical Inc Dec-2025 Annual Net Profit is $-575 Million which is growth of -1.0% YoY.

Ultragenyx Pharmaceutical Inc., Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	TTM	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
SR_A Total Rev. Ann. ⌄	22.8%	20%		673	560.2	434.3	363.3	351.4	271	103.7	51.5	2.6	0.1
TotalOperatingRevenues_A Operating Rev. Ann.	22.8%	20%	717.2	673	560.2	434.3	363.3	351.4	271	103.7	51.5	2.6	0.1
CostOfRevenue_A Cost Of Rev. Ann.	56.8%	78%	121.3	109	76.7	45.2	28.3	16	6.1	9	1.2		-	-
GrossProfit_A Gross Profit Ann.	19%	16.3%	595.9	564	483.5	389	335	335.4	264.9	94.7	50.4	2.6	-	-
OEXPNS_A Operating Exp. Ann.	3.8%	13.1%	1,124	1,099	1,019.5	958.3	983.9	717.1	595	518.9	421.7	331.6	248.1	147.7
OP_A Operating Profit Ann.	-	-	-528.2	-535	-536	-569.2	-648.9	-381.7	-330.1	-424.2	-371.4	-328.9	-248	-147.7
NetNonOperIntIncExp_A Net Non Operations Interest Incuding Expenses Ann, ⌄	-	-	-53.2	-37	-26.5	-39.3	-31.9	-27.5	-26.3	12.1	9.5	4.1	3.8	2.3
Others_A Other Interest Earned Ann.	31.1%	29%	23.4	25	36.5	26.7	11.1	1.9	7	13.2	9.5	4.1	3.8	2.3
IntExpNonOperating_A Interest Exp. Non Operating Ann.	13%	13.2%	76.6	62	63	66	43	29.4	33.3	1.1	-	-	-	-
OtherExpenses_A Other Exp. Ann.	-	-64.2%		1	-5.1	0.1	-20.9	-43.8	171	12.6	164.7	6.5	-1.6	-0.2
PBT_A PBT Ann.	-	-	-582.2	-571	-567.6	-608.5	-701.7	-453	-185.4	-399.4	-197.1	-318.3	-245.8	-145.6
TAX_A Tax Ann.	-11.1%	27.2%	3.7	4	1.6	-1.8	5.7	1	1.2	3.3	0.5	-16.2	0	-
NICommonStockholders_A Net Income Common Stockholders Ann. ⌄	-	-	-586	-575	-569.2	-606.6	-707.4	-454	-186.6	-402.7	-197.6	-302.1	-245.9	-145.6
NP_A Net Profit Ann.	-	-	-586	-575	-569.2	-606.6	-707.4	-454	-186.6	-402.7	-197.6	-302.1	-245.9	-145.6
NIIncludingNoncontrollingInterests_A Net Income Including Non controlling Interests Ann.	-	-	-586	-575	-569.2	-606.6	-707.4	-454	-186.6	-402.7	-197.6	-302.1	-245.9	-145.6
DilutedNIAvailtoComStockholders_A Diluted NI Avail to Com Stockholders Ann.	-	-	-586	-575	-569.2	-606.6	-707.4	-454	-186.6	-402.7	-197.6	-302.1	-245.9	-145.6
EPS_A EPS Ann.	-	-		-5.8	-6.3	-8.3	-10.1	-6.7	-3.1	-7.1	-4	-7.1	-6.2	-4
DilutedEPS_A Diluted EPS Ann.	-	-		-5.8	-6.3	-8.3	-10.1	-6.7	-3.1	-7.1	-4	-7.1	-6.2	-4
SHARE_Q Number Of Shares End	12.4%	9.1%		99.8	95.7	81.2	70.2	68.6	64.7	57.8	50.8	43.2	40.8	38.9
TotalExpenses_A Total Exp. Ann.	6.1%	15%		1,208	1,096.2	1,003.5	1,012.3	733.1	601.2	527.9	422.9	331.6	248.1	147.7
NIContinuingDiscontinuedOper_A Net Income Continuing Discontinued Operations Ann.	-	-	-586	-575	-569.2	-606.6	-707.4	-454	-186.6	-402.7	-197.6	-302.1	-245.9	-145.6
NormalizedIncome_A Normalized Income Ann.	-	-	-586.5	-575	-568.3	-607	-692.2	-423.3	-311	-412.5	-322	-302.1	-245.9	-145.6
InterestIncome_A Interest Income Ann.	31.1%	29%	23.4	25	36.5	26.7	11.1	1.9	7	13.2	9.5	4.1	3.8	2.3
INT_A Interest Ann.	13%	13.2%	76.6	62	63	66	43	29.4	33.3	1.1	-	-	-	-
EBITDA_A EBITDA Ann.	-	-	-472.2	-474	-469	-516.5	-640.5	-410.3	-139.8	-389.8	-351.8	-323.1	-244.6	-146.4
ReconciledCostOfRevenue_A Reconciled Cost Of Rev. Ann.	56.8%	78%	121.3	109	76.7	45.2	28.3	16	6.1	9	1.2		-	-
ReconciledDepreciation_A Reconciled Depr. Ann.	24.4%	23.3%	33.4	35	35.5	26	18.2	13.2	12.3	8.5	19.5	5.8	3.4	1.4
ProfitLossFromContinuingOperations_A Profit From Continuing Operations Ann.	-	-	-586	-575	-569.2	-606.6	-707.4	-454	-186.6	-402.7	-197.6	-302.1	-245.9	-145.6
NormalizedEBITDA_A Normalized EBITDA Ann.	-	-	-472.9	-474	-467.9	-516.9	-621.2	-368.3	-310.2	-403.2	-522.2	-323.1	-244.6	-146.4

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Total Rev. Ann.

1Y CHG

20.1%

2Y CAGR

24.5%

3Y CAGR

22.8%

5Y CAGR

20%

7Y CAGR

44.4%

Total Revenue Annual growth is stable compared to historical averages.

Operating Exp. Ann.

1Y CHG

7.8%

2Y CAGR

7.1%

3Y CAGR

3.8%

5Y CAGR

13.1%

7Y CAGR

14.7%

10Y CAGR

22.2%

Operating Expenses Annual Cr growth is stable compared to historical averages.

Ultragenyx Pharmaceutical Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Total Shareholders Fund Ultragenyx Pharmaceutical Inc Dec-2025 Total Shareholders Fund is $-80 Million which is growth of -131.3% YoY.
POSITIVE
Total Assets Ultragenyx Pharmaceutical Inc Dec-2025 Total Assets is $1,532 Million which is growth of 1.9% YoY.

Ultragenyx Pharmaceutical Inc., Balance Sheet, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
TA_A Total Assets Ann. ⌄	-0.3%	-2.7%	1,532	1,503.5	1,491	1,545.4	1,522.4	1,759.6	1,135.5	719.6	490.8	540.6	559.6
CA_A Total Current Assets Ann.	2.5%	-6%	951	817.1	732.2	883.9	856.6	1,295.3	851	522.4	269.6	401.7	450.2
CashEquivalentsShortTermInvestments_A Cash Equivalents and Short Term Investments Ann.	-3.1%	-10.8%	680	610	577.2	747.8	740.2	1,201.5	755.2	459.7	234.5	380.2	437
Receivables_A Change In Account Receivables Ann.	57.4%	46.9%	158	121.8	73.4	40.5	28.4	23.1	32.8	12.7	5.2	-	-
Inventories_A Inventories Ann.	24.7%	31.7%	52	45	34	26.8	16.2	13.1	11.6	7.1	0.8	-	-
OtherCurrentAssets_A Other Current Assets Ann.	-4%	-	61	40.3	47.6	68.9	-	-	-	-	-	-	-
TotalNonCurrentAssets_A Total Non Current Assets Ann.	-4.2%	4.6%	581	686.3	758.8	661.5	665.8	464.3	284.5	197.2	221.2	138.9	109.4
NetPPE_A Net PPE Ann.	-5.1%	16.4%	244	265.9	290.6	285.7	176.2	114	74.7	20.1	21.8	17.1	7.4
InvestmentsAndAdvances_A Investments & Advances Ann.	-28.3%	-19.2%	57	135	199.9	154.5	293.9	165.9	32.9		10	118	99.3
OtherNonCurrentAssets_A Other Non Current Assets Ann.	52.6%	46.8%	60	62.7	57.7	16.9	20.6	8.8	3.5	3.5	3.4	3.9	2.7
TotalLiabilitiesNetMinorityInterest_A Total Liabilities Net Minority Interest Ann. ⌄	10.4%	21.5%	1,605	1,241.2	1,215.6	1,193	599.8	605.2	481.7	110.7	107.3	66.7	28.5
CL_A Total Current Liabilities Ann.	13.7%	15.2%	384	344.2	280.4	261.2	181.4	189.6	103.3	74.7	71	60.3	27.9
PayablesAndAccruedExpenses_A Payables & Accrued Exp.s Ann.	-1.2%	14.5%	239	246.4	238.6	248	162.7	121.4	96.1	74.7	64.3	59.9	27.7
CurrentDebtCapLeaseObligation_A Current Debt Cap Lease Obligation Ann.	0.6%	5.9%	12	10.3	12.6	11.8	11.1	9	7.2	-	-	-	-
CurrentDeferredLiabilities_Q Current Deferred Liabilities	-	-	-	-		1.5	7.6	59.2	-		6.7	0.3	0.2
OtherCurrentLiabilities_A Other Current Liabilities Ann.	-	-	76	54.1	29.2	-	-	-	-	-	-	-	-
TotalNonCurrentLiabilities_A Total Non Current Liabilities Ann.	9.4%	24.1%	1,221	897	935.2	931.7	418.5	415.6	378.4	35.9	36.3	6.4	0.6
LongTermDebtAndCapitalLeaseObligation_Q LT Debt & Capital Lease Obligation	6.6%	-9.4%	24	30	30.6	19.8	30.9	39.3	29.8	-	-	-	-
TradeandOtherPayablesNonCurrent_A Trade & Other Payables Non Current Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalDeferredCreditsAndOtherNonCurrentLiabilities_A Total Deferred Credits & Other Non Current Liabilities Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalShareHoldersFunds_A Total ShareHolders Funds Ann. ⌄	-	-	-80	255.3	275.4	352.5	922.6	1,154.4	653.8	608.9	383.5	474	531.1
EQCAP_A Equity Share Capital Ann.	-	-	-80	255.3	275.4	352.5	922.6	1,154.4	653.8	608.9	383.5	474	531.1
CapitalStock_A Capital Stock Ann.	0%	0%		0.1	0.1	0.1	0.1	0.1	0.1	0.1	0	0	0
RetainedEarnings_A Retained Earnings Ann.	-	-	-4,532	-3,956.8	-3,387.7	-2,781	-2,073.6	-1,619.6	-1,433	-1,030.3	-832.7	-530.5	-284.7
GainsLossesNotAffectingRetainedEarnings_A Gains Losses Not Affecting Retained Earnings Ann.	-	7.4%	1	-0.6	0.7	-6.6	-1.4	0.7	-0.2	-0.6	-5.7	0.9	-0.9
TotalCapitalization_A Total Capitalization Ann.	-	-	-80	255.3	275.4	352.5	922.6	1,154.4	653.8	608.9	383.5	474	531.1
TangibleAssets_A Tangible Assets Ann.	-	-	-300	32.6	64.7	148	747.4	978.9	480.4	435.3	197.5	474	531.1
WC_A Working Capital Ann.	-3.1%	-12.5%	567	473	451.8	622.7	675.2	1,105.7	747.7	447.6	198.6	341.4	422.3
InvestedCapital_A Invested Capital Ann.	-	-	-80	255.3	275.4	352.5	922.6	1,154.4	653.8	608.9	383.5	474	531.1
TangibleBookValue_A Tangible Book Value Ann.	-	-	-300	32.6	64.7	148	747.4	978.9	480.4	435.3	197.5	474	531.1
Borrowings_A Borrowings Ann.	4.4%	-5.7%	36	40.3	43.2	31.6	42	48.2	37	-	-	-	-
NetDebt_A Net Debt Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
ShareIssued_A Share Issued Ann.	11.3%	7.7%	96.7	92.6	82.3	70.2	69.3	66.8	57.8	50.9	44.2	41.2	38.9
SHARE_Q Number Of Shares End	12.4%	9.1%	99.8	95.7	81.2	70.2	68.6	64.7	57.8	50.8	43.2	40.8	38.9

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Total Assets Ann.

1Y CHG

1.9%

2Y CAGR

1.4%

3Y CAGR

-0.3%

5Y CAGR

-2.7%

7Y CAGR

11.4%

10Y CAGR

10.6%

Total Assets Annual growth is stable compared to historical averages.

Total Current Liabilities Ann.

1Y CHG

11.6%

2Y CAGR

17%

3Y CAGR

13.7%

5Y CAGR

15.2%

7Y CAGR

26.3%

10Y CAGR

30%

Total Current Liabilities Annual Cr growth is lower than historical averages.

Ultragenyx Pharmaceutical Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Book Value Per Share Ultragenyx Pharmaceutical Inc Book Value Per Share is $-3 which is growth of -288.0% YoY.
NEUTRAL
ROE Ultragenyx Pharmaceutical Inc ROE is 0% which is growth of 0% YoY.

Ultragenyx Pharmaceutical Inc., Ratios, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
ROA_A RoA Ann. %	-	-	-	-38.02%	-39.96%	-46.12%	-27.67%	-12.89%	-43.42%	-32.65%	-58.59%	-44.70%	-38.45%
ROE_A ROE Ann. %	-	-	-	-214.50%	-193.23%	-110.96%	-43.72%	-20.64%	-63.79%	-39.83%	-70.48%	-48.93%	-40.67%
ROIC_Q ROIC %	-	-	-	-37.7	-57.8	-32.1	-12.4	-2	-13.2	-14.1	-22	-15.5	-10.1
OPMPCT_A OPM Ann. %	-	-	-79.49%	-95.67%	-131.08%	-178.60%	-108.63%	-121.80%	-408.98%	-721.18%	-12,593.49%	-186,471.43%	-
NBTO_A Inventory Turnover Ratio Ann.	-	-	-	1.9	1.5	1.3	1.1	0.5	1	0.3		-	-
ASETTO_A Asset Turnover Ann. %	-	-	-	0.4	0.3	0.2	0.2	0.2	0.1	0.1	0		-
WCTO_A Working Capital Turnover Ann.	26%	32%	1.2	1.2	1	0.6	0.5	0.3	0.1	0.1	0
QuickRatio_A Quick Ratio Ann.	-	-	-	2.1	2.3	3	4.2	6.5	7.6	6.3	3.4	6.3	15.7
CRATIO_A Current Ratio Ann.	-	-	-	2.4	2.6	3.4	4.7	6.8	8.2	7	3.8	6.7	16.1
IC_A Interest Coverage Ratio Ann.	-	-	-	-8	-8.2	-15.3	-14.4	-4.6	-350.9	-	-	-	-
LTDE_A LT Debt To Equity Ann.	-	-	-	0.1	0.1	0.1	0	0	0.1	-	-	-	-

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Ultragenyx Pharmaceutical Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Cash From Operating Activity Ultragenyx Pharmaceutical Inc Dec-2025 Cash From Operating Activity is $-466 Million which is growth of -12.5% YoY.
POSITIVE
Net Cash Flow Ultragenyx Pharmaceutical Inc Dec-2025 Net Cash Flow is $248 Million which is growth of 858.1% YoY.

Ultragenyx Pharmaceutical Inc., Cash Flow, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
CFO_A Cash from Operating Act. Ann. ⌄	-	-	-466	-414.2	-474.8	-380.5	-338.7	-132.2	-345.4	-290.6	-253.8	-161	-106
ProfitLossFromContinuingOperations_A Profit From Continuing Operations Ann.	-	-	-575	-569.2	-606.6	-707.4	-454	-186.6	-402.7	-197.6	-302.1	-245.9	-145.6
DepreciationAmortizationDepletion_A Depreciation Amortization Depletion Ann.	24.4%	23.3%	35	35.5	26	18.2	13.2	12.3	8.5	19.5	5.8	3.4	1.4
DepreciationAndAmortization_A Depreciation And Amortization Ann.	24.4%	23.3%	35	35.5	26	18.2	13.2	12.3	8.5	19.5	5.8	3.4	1.4
DeferredTax_A Deferred Tax Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
DeferredIncomeTax_A Deferred Income Tax Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
EmployeesStockOptions_A ESOPs Ann.	5.5%	12.3%	153	158	135.2	130.4	105	85.7	82	80.1	68	48.3	24.9
OtherNonCashItems_A Other Non Cash Items Ann.	-	-	-52	-41	-1.1	96.1	11.7	21.5	1.7	-0.2	-	0.7	-
ChangeInWorkingCapital_A Change In Working Capital Ann.	-	-	-23	13.9	-15.1	60.2	-63.2	104.7	-15.9	-24.8	-20.2	26.3	7.7
ChangeInReceivables_A Change In Receivables Ann.	-	-	-31	-33.6	-22.8	-12.1	-5.4	9.8	-20.1	-7.6	-	-	-
ChangeInInventory_A Change In Inventory Ann.	-	-	-6	-11.2	-6.9	-9.7	-3.1	-1.4	-4.5	-5.3	-	-	-
ChangePayablesAccruedExpense_A Change Payables Accrued Expense Ann.	-35%	-2.3%	24	47	2.4	87.4	32.3	26.9	13.3	2.4	-1.2	34.7	14.7
ChangeInOtherCurrentAssets_A Change In Other Current Assets Ann.	-	-	-	-	-	-	-	-	-	-0.4	0.5	-1.2	0.2
ChangeInOtherCurrentLiabilities_A Change In Other Current Liabilities Ann.	-	-	-	-	-	-	-	-	15.6	-	-	-	-
ChangeInOtherWorkingCapital_A Change In Other Working Capital Ann.	-	-	-	-	-3.1	-9.2	-57.5	66.6	-12	-0.4	-16.3	-1.2	0.2
CFI_A Cash from Investing Act. Ann. ⌄	-	-	236	-17.8	168	-291.7	-195.4	-179.1	-13	-33.3	56.4	89.9	-292.4
NetPPEPurchaseAndSale_A Net PPE Purchase & Sale Ann.	-	-	-6	-7.5	-44.3	-116.1	-73.1	-43.9	-24.8	-4.1	-2.8	-10.2	-5
PurchaseOfPPE_A Purchase Of PPE Ann.	-	-	-6	-7.5	-44.3	-116.1	-73.1	-43.9	-24.8	-4.1	-2.8	-10.2	-5
NetBusinessPurchaseAndSale_A Net Business Purchase & Sale Ann.	-	-	-			-75	-	-			-142.8	-	-
PurchaseOfBusiness_A Purchase Of Business Ann.	-	-	-			-75	-	-			-142.8	-	-
PurchaseOfInvestment_A Purchase Of Investment Ann.	-	-	-186	-408.6	-526.4	-614.7	-1,012.2	-850.3	-707.2	-509.8	-230.5	-442.5	-624.2
SaleOfInvestment_A Sale Of Investment Ann.	-6.6%	-9.2%	444	413.3	746.2	545.1	890.9	720.6	719	310.2	431.6	543.8	338.4
NetOtherInvestingChanges_A Net Other Investing Changes Ann.	-	-	-1	-2.4	-5.1	-0.8	-0.9	-5.6	-	170.3	0.9	-1.2	-1.5
CFA_A Cash from Financing Act. Ann. ⌄	-1.6%	-4.5%	478	399.2	388.1	501.2	118.6	600.3	679.3	336.9	136.3	138.7	467.6
NetIssuancePaymentsOfDebt_A Net Issuance Payments Of Debt Ann.	-	-	-	-	-	-	-	-			-4.9	-	-
NetLongTermDebtIssuance_A Net Long Term Debt Issuance Ann.	-	-	-	-	-	-	-	-			-4.9	-	-
NetShortTermDebtIssuance_A Net ST Debt Issuance Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
NetCommonStockIssuance_A Net Common Stock Issuance Ann.	-	-30%	86	381	379.8		78.9	511.2	355.2	309	132	79.5	467.6
CommonStockIssuance_A Common Stock Issuance Ann.	-	-30%	86	381	379.8		78.9	511.2	355.2	309	132	79.5	467.6
CommonStockPayments_A Common Stock Payments Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
dividend_1Y_actual Dividend 1year	-	-
DividendPerShare_A Dividend Per Share Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
NetOtherFinancingCharges_A Net Other Financing Charges Ann.	-7.2%	-	392	7	-0	490.4	-0.5	-0.2	314.2	-	-	-	-
CashAndCashEquivalentEndOfYear_A Cash Plus Cash Eqv. End Of Year Ann.	46.9%	-9.7%	436	184.2	219.4	137.6	309.6	726.3	436.2	115.5	100.5	161.1	93.6
NetIncDecInCashAndCashEquivalents_A Net Increase In Cash Plus Cash Eqv.s Ann.	-	-3%	248	-32.7	81.3	-170.9	-415.5	288.9	320.9	13	-61.2	67.6	69.2
CashAndCashEquivalentBeginOfYear_A Cash Plus Cash Eqv. Begin Of Year Ann.	-15.9%	-15.9%	184	219.4	137.6	309.6	726.3	436.2	115.5	103	161.1	93.6	24.3
IncomeTaxPaidSupplementalData_A Income Tax Paid Supplemental Data Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
InterestPaidSupplementalData_A Interest Paid Supplemental Data Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
CapitalExpenditure_A Capex Ann.	-	-	-21	-20	-46.8	-146.1	-73.1	-43.9	-24.8	-4.1	-2.8	-10.2	-5
IssuanceOfCapitalStock_A Issuance Of Capital Stock Ann.	-	-30%	86	381	379.8		78.9	511.2	355.2	309	132	79.5	467.6
IssuanceOfDebt_A Issuance Of Debt Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
RepaymentOfDebt_A Repayment Of Debt Ann.	-	-	-	-	-	-	-	-			-4.9	-	-
RepurchaseOfCapitalStock_A Repurchase Of Capital Stock Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
FreeCashFlow_A Free Cash Flow Ann.	-	-	-487	-434.2	-521.6	-526.6	-411.8	-176.1	-370.2	-294.6	-256.6	-171.2	-110.9

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Cash from Investing Act. Ann.

2Y CAGR

18.5%

Cash from Investing Activity Annual growth is higher than historical averages.

Cash from Financing Act. Ann.

1Y CHG

19.7%

2Y CAGR

11%

3Y CAGR

-1.6%

5Y CAGR

-4.5%

7Y CAGR

5.1%

10Y CAGR

0.2%

Cash from Financing Annual Activity growth is higher than historical averages.

Forecaster
Quarterly
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow

63.65% Fall from 52W High

Ultragenyx Pharmaceutical Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

Ultragenyx Pharmaceutical Inc - Forecaster

Forecaster Analyst Estimates for Ultragenyx Pharmaceutical Inc share price target, revenues, EPS, net income and more

Ultragenyx Pharmaceutical Inc - Earnings Report - Quarterly Results

Ultragenyx Pharmaceutical Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Quarterly Revenue Ultragenyx Pharmaceutical Inc Jun-2026 Quarterly Revenue is $214 Million which is growth of 28.5% YoY.

Quarterly Net Profit Ultragenyx Pharmaceutical Inc Jun-2026 Quarterly Net Profit is $-92 Million which is growth of 20.0% YoY.

Ultragenyx Pharmaceutical Inc - Competitors/Peers

Ultragenyx Pharmaceutical Inc competitor comparison and performance snapshot within industry

Ultragenyx Pharmaceutical Inc - Earnings Report - Annual Results

Ultragenyx Pharmaceutical Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Annual Revenue Ultragenyx Pharmaceutical Inc Dec-2025 Annual Revenue is $673 Million which is growth of 20.1% YoY.

Annual Net Profit Ultragenyx Pharmaceutical Inc Dec-2025 Annual Net Profit is $-575 Million which is growth of -1.0% YoY.

Ultragenyx Pharmaceutical Inc - Balance Sheet

Ultragenyx Pharmaceutical Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Total Shareholders Fund Ultragenyx Pharmaceutical Inc Dec-2025 Total Shareholders Fund is $-80 Million which is growth of -131.3% YoY.

Total Assets Ultragenyx Pharmaceutical Inc Dec-2025 Total Assets is $1,532 Million which is growth of 1.9% YoY.

Ultragenyx Pharmaceutical Inc - Ratios

Ultragenyx Pharmaceutical Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Book Value Per Share Ultragenyx Pharmaceutical Inc Book Value Per Share is $-3 which is growth of -288.0% YoY.

ROE Ultragenyx Pharmaceutical Inc ROE is 0% which is growth of 0% YoY.

Ultragenyx Pharmaceutical Inc - Cash Flow

Ultragenyx Pharmaceutical Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Cash From Operating Activity Ultragenyx Pharmaceutical Inc Dec-2025 Cash From Operating Activity is $-466 Million which is growth of -12.5% YoY.

Net Cash Flow Ultragenyx Pharmaceutical Inc Dec-2025 Net Cash Flow is $248 Million which is growth of 858.1% YoY.